USP <1211>: The Compendial Informational Chapter on Sterility Assurance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP <1211>: The Compendial Informational Chapter on Sterility Assurance
The author provides a history of the information chapter USP 91211: "Sterilization and Sterility Assurance of Compendial Articles," from the early 1900s to the current version.


Pharmaceutical Technology


The current version

USP XX generated controversy in the industry, and given the emphasis placed on control of the sterilization process, additional detail was proposed in 1982 (17) for addition to the introductory section of the chapter, which was proposed to undergo a name change to "Sterilization and Sterility Assurance of Compendial Articles." This section described sterilization process validation as having an installation qualification, an operational qualification, a confirmatory stage, and a final stage (for completion of documentation). Selection and control of biological indicators for sterilization validation are described, as is a general review of process control subjects. Each method of sterilization included in the chapter is expanded to include at least a short discussion of validation concerns. There is a great deal of material added to the ionizing radiation and the filtration sections in this regard.

The 1982 Pharmacopeial Forum in-process revision draft also expanded the sterility testing section. Among the additions was a definition of product "lot" for sterility-test purposes and the assertion that a 1–2% false-positive rate was acceptable for the sterility test. This addition was viewed as justification for a second-stage test if the first-stage test failed.

A further revision (with extensive editorial rewrites) appeared in the May–June 1983 Pharmacopeial Forum (18) followed immediately by a second rewrite in the Sept.-Oct. Pharmacopeial Forum (19). The second draft of 1983 contained modest editorial changes, with the exception of the removal of a description of minimum standards for an aseptic manufacturing facility and some of the more onerous requirements for sterility testing (e.g., requiring the test facility be fully validated and the use of negative controls on the test). It was this version that appeared in USP XXI (20).

Refinements to the basic chapter were proposed in 1986 (21) to clarify some points regarding filtration and aseptic processing and to keep pace with changes in the contemporary sterility test chapter, primarily clarification of the bacteriostasis/fungistasis test (22). This version appeared in USP XXII (23).

Concerns were raised in the field about the handling of sterilization by filtration in the revised chapter and a proposed revision to address these concerns appeared in 1990 (24). These changes were accepted and appeared in USP 23 (25). The chapter has not changed appreciably since.

Revisions currently under consideration

The sterilization chapter is significantly, and obviously, in need of revision (26, 27). This task was attempted with a proposed short-term revision published in 2004 for review (28). The major changes proposed in the 2004 revision were:

  • Elimination of references to the old sterility test ‹71› and to first- and second-stage testing
  • Updating the names of microorganisms to current taxonomy
  • References to units of measure (Mrad) currently in use
  • Elimination of references to discontinued standards (especially Fed Standard 209)
  • Reference to new consensus standards (ISO 13408-1)
  • Discussion of contemporary aseptic processes.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here